Celyad Reports Publication Of CHART-1 Trial Design Methods Paper

(RTTNews) - Celyad (CYAD), engaged in the discovery and development of engineered cell therapies, Wednesday said that a methods paper on the Congestive Heart Failure Cardiopoietic Regenerative Therapy or CHART-1 clinical trial design has been published in the European Journal of Heart Failure or EJHF 2015.

CHART-1 is a patient prospective, controlled multi-centre, randomized, double-blinded Phase III clinical trial comparing treatment with C-Cure to a sham treatment.

The trial has recruited 240 patients with chronic advanced symptomatic heart failure in Europe and Israel.

The primary endpoint of the trial is a composite endpoint including mortality, morbidity, quality of life, Six Minute Walk Test and left ventricular structure and function at nine months post-procedure.

The next milestone in the clinical trial will be the release of the full clinical data set, expected to be in mid-2016.

Dr. Christian Homsy, CEO of Celyad, said: "The publication of the CHART-1 methods paper in the European Journal of Heart Failure is a scientific acknowledgement of the work that has been done around the design of our clinical trial for ischemic heart failure. We are proud of this achievement and we thank all the people who have been involved in the writing process."